Sarepta Therapeutics Inc (SRPT) saw an uptrend of 12639524% in the recent trading with $4790000.0 being its most recent. The current price level -88.41% lower than the highest price of $173.25 marked by the stock while trading over the past 52-weeks, whereas it is 9.73% higher than the lowest price of $18.30 the company dropped to over past 52-weeks. The latest news story on SRPT appeared in (Investor’s Business Daily) under the title “The FDA Shake-Up Continues, And Could Impact Genetic Medicines” on Jun-20-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 17 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.07 for the stock.
Sarepta Therapeutics Inc Earnings – What Happened With SRPT
Coming around sales and income figures on SRPT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Sarepta Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 98.25 million. SRPT does have institutional investors; and they hold 90.15% of the stock.
As on 2024-06-30, BLACKROCK INC. was the top most holder in Sarepta Therapeutics Inc (NASDAQ:SRPT) with an ownership of 10.32 million shares of the company or 10.9117 of the stake worth $1.63 billion. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 9.5496 of the outstanding shares. Its stake is worth $1.43 billion for having 9.04 million shares in hand.
CAPITAL INTERNATIONAL INVESTORS also came holding a key position in the company during the recent quarter and it now holds 4.5666 of the outstanding shares. With this there are now 625.0 institutions which have possession in SRPT’s shares.
Key Metrics forSRPT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Sarepta Therapeutics Inc has a debt to equity ratio of 1.18.
